Donepezil
Product Images NDC 50090-2910

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil (NDC 50090-2910). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Address1 (Address1)

Address1 (Address1)
FDA Label Image

Address2 (Address2)

Address2 (Address2)
FDA Label Image

Donepezilfigure10 (Donepezilfigure10)

Donepezilfigure10 (Donepezilfigure10)
FDA Label Image

Donepezilfigure8 (Donepezilfigure8)

Donepezilfigure8 (Donepezilfigure8)
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
This text seems to be a chart, showing the results of a study on the effects of Donepezil Hydrochloride and placebo on cognitive function. The chart lists different treatment groups and the percentage of improvement in cognitive function (measured by change in ADAS cog) compared to a placebo group. The dosage of Donepezil Hydrochloride varies from 5 mg/day to 10 mg/day. There is also a graph displaying the change from baseline for each treatment group.*
FDA Label Image

Figure3 (Figure3)

Figure3 (Figure3)
FDA Label Image

Figure4 (Figure4)

Figure4 (Figure4)
FDA Label Image

Figure5 (Figure5)

Figure5 (Figure5)
Cumulative percentage of patients that experienced change in ADAS-cog score after taking either Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, or placebo. The change from baseline was measured in the ADAS-cog score after the medication was administered. The results of this study showed that the percentage of patients who experienced a change in ADAS-cog score was 74% for those taking Donepezil Hydrochloride 10 mg/day, 72% for those taking Donepezil Hydrochloride 5 mg/day, and 50% for those taking placebo.*
FDA Label Image

Figure6 (Figure6)

Figure6 (Figure6)
FDA Label Image

Figure7 (Figure7)

Figure7 (Figure7)
This text is describing the dosage of a drug named Donepsl Hydrochloride, which is mentioned to be taken 10 ml per day. A placebo is also mentioned, which could be a reference to a control group where no actual drug is administered. The text does not provide any information about the purpose or effects of the drug, other than its dosage. Therefore, it cannot be used to generate a useful description.*
FDA Label Image

Figure9 (Figure9)

Figure9 (Figure9)
FDA Label Image

Label Image (Lbl500902627)

Label Image (Lbl500902627)
This is a product descriptor with the product number 6311-0. The text mentions "Lo7'" but it's not clear what it refers to. "BihgreziL wmanock oniof" is not a recognizable word or phrase. The product should be stored at 8 to 107 degrees but the unit of measurement is not specified.*
FDA Label Image

Label Image (Lbl500902910)

Label Image (Lbl500902910)
FDA Label Image

Structure (Structure)

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.